Patent expands coverage of therapeutic that addresses range of neurological conditions

A clinical-stage biopharma firm announced it has been granted a U.S. patent expanding coverage of a novel oral therapy to treat various conditions associated with loss-of-function mutations of the gene encoding methyl-CpG binding protein.
According to a press release from Anavex Life Sciences Corp., the patent claims protect use of Anavex2-73 (blarcamesine) for symptoms exhibited by patients with neurodevelopmental and neurological conditions related to McCP2, such as abnormalities in sleep, breathing, cardiac function, feeding, choking, lack of weight gain, seizures and abnormal amount of

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart
This website uses cookies and asks your personal data to enhance your browsing experience.